The stock of BridgeBio Pharma Inc (BBIO) has seen a 6.97% increase in the past week, with a 29.69% gain in the past month, and a 37.76% flourish in the past quarter. The volatility ratio for the week is 5.42%, and the volatility levels for the past 30 days are at 5.29% for BBIO. The simple moving average for the last 20 days is 20.18% for BBIO stock, with a simple moving average of 34.91% for the last 200 days.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
The 36-month beta value for BBIO is at 1.06. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 6 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BBIO is 147.77M, and currently, shorts hold a 13.06% of that float. The average trading volume for BBIO on January 22, 2025 was 2.24M shares.
BBIO) stock’s latest price update
BridgeBio Pharma Inc (NASDAQ: BBIO)’s stock price has increased by 6.78 compared to its previous closing price of 33.79. However, the company has seen a 6.97% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-01-15 that Attruby’s recent approval positions BBIO as a direct competitor to PFE’s Vyndaqel in ATTR-CM. Attruby has a 42% reduction of heart failure risk with 90% TTR stabilization. So I think it could have a superior profile in some cases relative to Vyndaqel. BBIO is now also set to receive $500 million in milestone payments related to Attruby’s approval, and I expect they’ll get an additional $105 million from EU and Japan approvals.
Analysts’ Opinion of BBIO
Piper Sandler gave a rating of “Overweight” to BBIO, setting the target price at $46 in the report published on September 04th of the previous year.
BBIO Trading at 30.25% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.09% of loss for the given period.
Volatility was left at 5.29%, however, over the last 30 days, the volatility rate increased by 5.42%, as shares surge +38.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.38% upper at present.
During the last 5 trading sessions, BBIO rose by +6.97%, which changed the moving average for the period of 200-days by +23.43% in comparison to the 20-day moving average, which settled at $30.02. In addition, BridgeBio Pharma Inc saw 31.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Kumar Neil, who sale 27,389 shares at the price of $22.41 back on Nov 19 ’24. After this action, Kumar Neil now owns 4,897,443 shares of BridgeBio Pharma Inc, valued at $613,826 using the latest closing price.
STEPHENSON BRIAN C, the Secretary, Treasurer & CFO of BridgeBio Pharma Inc, sale 4,156 shares at $22.41 during a trade that took place back on Nov 19 ’24, which means that STEPHENSON BRIAN C is holding 93,758 shares at $93,137 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -2.48 for the present operating margin
- 0.98 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -2.02. The total capital return value is set at -1.03.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 3.46 points at debt to capital in total, while cash flow to debt ratio is standing at -0.26. The debt to equity ratio resting at -1.41. The interest coverage ratio of the stock is -6.03.
Currently, EBITDA for the company is -565.47 million with net debt to EBITDA at -4.18. When we switch over and look at the enterprise to sales, we see a ratio of 38.03. The receivables turnover for the company is 455.58for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.19.
Conclusion
In conclusion, BridgeBio Pharma Inc (BBIO) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
